These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29064022)

  • 1. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.
    Pemmaraju N
    Curr Hematol Malig Rep; 2017 Dec; 12(6):510-512. PubMed ID: 29064022
    [No Abstract]   [Full Text] [Related]  

  • 2. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
    Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
    Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
    [No Abstract]   [Full Text] [Related]  

  • 3. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
    Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
    Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
    Agha ME; Monaghan SA; Swerdlow SH
    N Engl J Med; 2018 Oct; 379(15):1479-1481. PubMed ID: 30304659
    [No Abstract]   [Full Text] [Related]  

  • 7. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY; Konopleva M; Pemmaraju N
    Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
    Tandon A; Zhang Y; Sokol L
    Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
    Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Lane AA
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):589-600. PubMed ID: 32336422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ; Wilson NR; Pemmaraju N
    Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; McCue D; Lane AA; Pemmaraju N
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
    [No Abstract]   [Full Text] [Related]  

  • 14. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
    Wu SJ; Sadigh S; Lane AA; Pinkus GS
    Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
    J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
    Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
    J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
    Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
    Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
    Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
    Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Luskin MR; Lane AA
    Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.